Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 4/2020

01-08-2020 | Churg-Strauss Syndrome | Review Article

Eosinophilic Dermatoses: Recognition and Management

Authors: Angelo Valerio Marzano, Giovanni Genovese

Published in: American Journal of Clinical Dermatology | Issue 4/2020

Login to get access

Abstract

Eosinophilic dermatoses encompass a broad spectrum of diseases of different etiologies hallmarked by eosinophilic infiltration of the skin and/or mucous membranes, with or without associated blood eosinophilia. The wide range of dermatological manifestations of this spectrum, including nodules and plaques, pustules, blisters, ulcers, and urticarial lesions, is reflected in a non-univocal classification system. We identified six groups of eosinophilic dermatoses based on the predominant anatomic level of involvement: (1) epidermal; (2) of the dermal–epidermal junction; (3) dermal; (4) of the hypodermis and muscle fascia; (5) of the pilosebaceous unit; and (6) vascular/perivascular. We review clinicopathologic features and management of diseases belonging to each group, particularly: (1) pemphigus herpetiformis and atopic dermatitis as prototypes of the epidermal group; (2) bullous pemphigoid as prototypic eosinophilic dermatosis of the dermal–epidermal junction; (3) eosinophilic cellulitis (Wells syndrome), hypereosinophilic syndromes, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, eosinophilic dermatosis of hematologic malignancy and chronic spontaneous urticaria as paradigmatic dermal eosinophilic dermatoses; (4) eosinophilic fasciitis as an eosinophilic dermatosis with predominant involvement of the hypodermis and muscle fascia; (5) eosinophilic pustular folliculitis as a model of the pilosebaceous unit involvement; and (6) granuloma faciale, angiolymphoid hyperplasia with eosinophilia, and eosinophilic granulomatosis with polyangiitis, belonging to the vascular/perivascular group.
Literature
1.
Peckruhn M, Elsner P, Tittelbach J. Eosinophilic dermatoses. J Dtsch Dermatol Ges. 2019;17:1039–51.PubMed
2.
Leiferman KM, Peters MS. Eosinophil-related disease and the skin. J Allergy Clin Immunol Pract. 2018;6:1462–82 (e6).PubMed
3.
Simon D, Simon HU. Eosinophilic disorders. J Allergy Clin Immunol. 2007;120:515.
4.
Jablonska S, Chorzelski TP, Beutner EH, Chorzelska J. Herpetiform pemphigus, a variable pattern of pemphigus. Int J Dermatol. 1975;14:353–9.PubMed
5.
Crotty C, Pittelkow M, Muller SA. Eosinophilic spongiosis: a clinicopathologic review of seventy-one cases. J Am Acad Dermatol. 1983;8:337–43.PubMed
6.
Kasperkiewicz M, Kowalewski C, Jabłońska S. Pemphigus herpetiformis: from first description until now. J Am Acad Dermatol. 2014;70:780–7.PubMed
7.
O’Toole EA, Mak LL, Guitart J, Woodley DT, Hashimoto T, Amagai M, et al. Induction of keratinocyte IL-8 expression and secretion by IgG autoantibodies as a novel mechanism of epidermal neutrophil recruitment in a pemphigus variant. Clin Exp Immunol. 2000;119:217–24.PubMedPubMedCentral
8.
Robinson ND, Hashimoto T, Amagai M, Chan LS. The new pemphigus variants. J Am Acad Dermatol. 1999;40:649–71.PubMed
9.
de Graauw E, Beltraminelli H, Simon HU, Simon D. Eosinophilia in dermatologic disorders. Immunol Allergy Clin N Am. 2015;35:545–60.
10.
Hossny E, Aboul-Magd M, Bakr S. Increased plasma eotaxin in atopic dermatitis and acute urticaria in infants and children. Allergy. 2001;56:996–1002.PubMed
11.
Kiehl P, Falkenberg K, Vogelbruch M, Kapp A. Tissue eosinophilia in acute and chronic atopic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. Br J Dermatol. 2001;145:720–9.PubMed
12.
Leiferman KM, Ackerman SJ, Sampson HA, Haugen HS, Venencie PY, Gleich GJ. Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis: comparison with onchocerciasis. N Engl J Med. 1985;313:282–5.PubMed
13.
Roth N, Stadler S, Lemann M, Hosli S, Simon HU, Simon D. Distinct eosinophil cytokine expression patterns in skin diseases: the possible existence of functionally different eosinophil subpopulations. Allergy. 2011;66:1477–86.PubMed
14.
Morshed M, Yousefi S, Stockle C, Simon HU, Simon D. Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps. Allergy. 2012;67:1127–37.PubMed
15.
Simon D, Aeberhard C, Erdemoglu Y, Simon HU. Th17 cells and tissue remodeling in atopic and contact dermatitis. Allergy. 2014;69:125–31.PubMed
16.
Simon D, Borradori L, Simon HU. Eosinophils as putative therapeutic targets in bullous pemphigoid. Exp Dermatol. 2017;26:1187–92.PubMed
17.
de Graauw E, Sitaru C, Horn M, Borradori L, Yousefi S, Simon HU, et al. Evidence for a role of eosinophils in blister formation in bullous pemphigoid. Allergy Eur J Allergy Clin Immunol. 2017;72:1105–13.
18.
Kridin K. Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation. Br J Dermatol. 2018;179:1141–7.PubMed
19.
Genovese G, Di Zenzo G, Cozzani E, Berti E, Cugno M, Marzano AV. New insights into the pathogenesis of bullous pemphigoid: 2019 update. Front Immunol. 2019;10:1506.PubMedPubMedCentral
20.
Rüdrich U, Gehring M, Papakonstantinou E, Illerhaus A, Engmann J, Kapp A, et al. Eosinophils are a major source of interleukin-31 in bullous pemphigoid. Acta Dermatovenereol. 2018;98:766–71.
21.
Dresow SK, Sitaru C, Recke A, Oostingh GJ, Zillikens D, Gibbs BF. IgE autoantibodies against the intracellular domain of BP180. Br J Dermatol. 2009;160:429–32.PubMed
22.
Cozzani E, Gasparini G, Di Zenzo G, Parodi A. Immunoglobulin E and bullous pemphigoid. Eur J Dermatol. 2018;28:440–8.PubMed
23.
Messingham KN, Holahan HM, Frydman AS, Fullenkamp C, Srikantha R, Fairley JA. Human eosinophils express the high affinity IgE receptor, FceRI, in bullous pemphigoid. PLoS One. 2014;9:e107725.PubMedPubMedCentral
24.
Lin L, Hwang BJ, Culton DA, Li N, Burette S, Koller BH, et al. Eosinophils mediate tissue injury in the autoimmune skin disease bullous pemphigoid. J Investig Dermatol. 2018;138:1032–43.PubMed
25.
Marzano AV, Tedeschi A, Berti E, Fanoni D, Crosti C, Cugno M. Activation of coagulation in bullous pemphigoid and other eosinophil-related inflammatory skin diseases. Clin Exp Immunol. 2011;165:44–50.PubMedPubMedCentral
26.
Marzano AV, Tedeschi A, Fanoni D, Bonanni E, Venegoni L, Berti E, et al. Activation of blood coagulation in bullous pemphigoid: role of eosinophils, and local and systemic implications. Br J Dermatol. 2009;160:266–72.PubMed
27.
Tedeschi A, Marzano AV, Lorini M, Balice Y, Cugno M. Eosinophil cationic protein levels parallel coagulation activation in the blister fluid of patients with bullous pemphigoid. J Eur Acad Dermatol Venereol. 2015;29:813–7.PubMed
28.
Cugno M, Marzano AV, Bucciarelli P, Balice Y, Cianchini G, Quaglino P, INVENTEP Study Group, et al. Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) study. Thromb Haemost. 2016;115:193–9.PubMed
29.
Wells GC. Recurrent granulomatous dermatitis with eosinophilia. Trans St Johns Hosp Dermatol Soc. 1971;57:46–56.PubMed
30.
Moossavi M, Mehregan DR. Wells’ syndrome: a clinical and histopathologic review of seven cases. Int J Dermatol. 2003;42:62–7.PubMed
31.
Yu AM, Ito S, Leibson T, Lavi S, Fu LW, Weinstein M, Skotnicki SM. Pediatric Wells syndrome (eosinophilic cellulitis) after vaccination: a case report and review of the literature. Pediatr Dermatol. 2018;35:e262–e264264.PubMed
32.
Caputo R, Marzano AV, Vezzoli P, Lunardon L. Wells syndrome in adults and children: a report of 19 cases. Arch Dermatol. 2006;142:1157–61.PubMed
33.
Peckruhn M, Tittelbach J, Schliemann S, Elsner P. Life of lesions in eosinophilic cellulitis (Wells’ syndrome): a condition that may be missed at first sight. Am J Dermatopathol. 2015;37:e15–e1717.PubMed
34.
Weins AB, Biedermann T, Weiss T, Weiss JM. Wells syndrome. J Dtsch Dermatol Ges. 2016;14:989–93.PubMed
35.
Brasileiro LG, Abreu MAMM, Paschoal RS. Wells’ syndrome: the importance of differential diagnosis. An Bras Dermatol. 2019;94:370–2.PubMedPubMedCentral
36.
Ratzinger G, Zankl J, Zelger B. Wells syndrome and its relationship to Churg–Strauss syndrome. Int J Dermatol. 2013;52:949–54.PubMed
37.
French LE, Shapiro M, Junkins-Hopkins JM, Wolfe JT, Rook AH. Eosinophilic fasciitis and eosinophilic cellulitis in a patient with abnormal circulating clonal T cells: increased production of interleukin 5 and inhibition by interferon alfa. J Am Acad Dermatol. 2003;49:1170–4.PubMed
38.
Fujii K, Tanabe H, Kanno Y, Konishi K, Ohgou N. Eosinophilic cellulitis as a cutaneous manifestation of idiopathic hypereosinophilic syndrome. J Am Acad Dermatol. 2003;49:1174–7.PubMed
39.
Räßler F, Lukács J, Elsner P. Treatment of eosinophilic cellulitis (Wells syndrome): a systematic review. J Eur Acad Dermatol Venereol. 2016;30:1465–79.PubMed
40.
Karabudak O, Dogan B, Taskapan O, Harmanyeri Y. Eosinophilic cellulitis presented with semicircular pattern. J Dermatol. 2006;33:798–801.PubMed
41.
Herr H, Koh JK. Eosinophilic cellulitis (Wells’ syndrome) successfully treated with low-dose cyclosporine. J Korean Med Sci. 2001;16:664–8.PubMedPubMedCentral
42.
Kim SH, Kwon JE, Kim HB. Successful treatment of steroid-dependent eosinophilic cellulitis with cyclosporine. Allergy Asthma Immunol Res. 2013;5:62–4.PubMed
43.
Coelho de Sousa V, Laureano Oliveira A, Cardoso J. Successful treatment of eosinophilic cellulitis with dapsone. Dermatol Online J. 2016;22:13030.PubMed
44.
Bokotas C, Kouris A, Stefanaki C, Sgotzou T, Christofidou E, Kontochristopoulos G. Wells syndrome: response to dapsone therapy. Ann Dermatol. 2014;26:541–2.PubMedPubMedCentral
45.
Moon SH, Shin MK. Bullous eosinophilic cellulitis in a child treated with dapsone. Pediatr Dermatol. 2013;30:e46–e4747.PubMed
46.
Egeland Ø, Balieva F, Undersrud E. Wells syndrome: a case of successful treatment with omalizumab. Int J Dermatol. 2018;57:994–5.PubMed
47.
Ogueta I, Spertino J, Deza G, Alcantara Luna S, Zaragoza Ninet V, Pujol RM, et al. Wells syndrome and chronic spontaneous urticaria: report of four cases successfully treated with omalizumab. J Eur Acad Dermatol Venereol. 2019;33:e388–e391391.PubMed
48.
49.
Herout S, Bauer WM, Schuster C, Stingl G. Eosinophilic cellulitis (Wells syndrome) successfully treated with mepolizumab. JAAD Case Rep. 2018;4:548–50.PubMedPubMedCentral
50.
Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124:1319–25 (e3).PubMedPubMedCentral
51.
Inayat F, O'Neill SS, Zafar F, Marupudi S, Vasim I. Idiopathic hypereosinophilic syndrome with cutaneous involvement: a comparative review of 32 cases. BMJ Case Rep. 2018;11(1):bcr2018227137.
52.
Leiferman KM, Gleich GJ, Peters MS. Dermatologic manifestations of the hypereosinophilic syndromes. Immunol Allergy Clin N Am. 2007;27:415–41.
53.
Valent P, Klion AD, Rosenwasser LJ, Arock M, Bochner BS, Butterfield JH, et al. ICON: eosinophil disorders. World Allergy Organ J. 2012;5:174–81.PubMedPubMedCentral
54.
Plötz SG, Hüttig B, Aigner B, Merkel C, Brockow K, Akdis C, et al. Clinical overview of cutaneous features in hypereosinophilic syndrome. Curr Allergy Asthma Rep. 2012;12:85–988.PubMed
55.
Lefèvre G, Copin MC, Staumont-Sallé D, Avenel-Audran M, Aubert H, Taieb A, French Eosinophil Network, et al. The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3–CD4+ aberrant T-cell phenotype. Medicine (Baltimore). 2014;93:255–66.
56.
Simon HU, Plötz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341:1112–20.PubMed
57.
Plötz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med. 2003;349:2334–9.PubMed
58.
59.
González Delgado P, de la Sen Fernández ML, Soriano Gomis V, Pérez Crespo M, Muñoz Ruiz C, Hernández NE. Cyclical hypereosinophilia with skin manifestations and a clonal T cell population. J Investig Allergol Clin Immunol. 2008;18:401–3.PubMed
60.
Hayashi M, Kawaguchi M, Mitsuhashi Y, Suzuki T. Case of hypereosinophilic syndrome with cutaneous necrotizing vasculitis. J Dermatol. 2008;35:229–33.PubMed
61.
Klion AD, Mejia R, Cowen EW, Dowdell KC, Dunleavy K, Fahle GA, et al. Chronic active Epstein–Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome. Blood. 2013;121:2364–6.PubMedPubMedCentral
62.
d’Elbée JM, Parrens M, Mercié P, Longy Boursier M, Dieval C, de Mascarel A, et al. Hypereosinophilic syndrome: lymphocytic variant transforming into peripheral T-cell lymphoma with severe oral manifestations. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116:e185–e190190.PubMed
63.
Merlotto MR, Cantadori LO, Sakabe D, Miot HA. Case for diagnosis: erythroderma as manifestation of hypereosinophilic syndrome. An Bras Dermatol. 2018;93:451–3.PubMedPubMedCentral
64.
Sundaramurthi VL, Prabhavathy D, Somasundaram SV, Wahab AJ. Hypereosinophilic syndrome: cutaneous involvement as the sole manifestation. Indian J Dermatol. 2011;56:107–9.PubMedPubMedCentral
65.
Bogenrieder T, Griese DP, Schiffner R, Büttner R, Riegger GA, Hohenleutner U, et al. Wells’ syndrome associated with idiopathic hypereosinophilic syndrome. Br J Dermatol. 1997;137:978–82.PubMed
66.
Kazmierowski JA, Chusid MJ, Parrillo JE, Fauci AS, Wolff SM. Dermatologic manifestations of the hypereosinophilic syndrome. Arch Dermatol. 1978;114:531–5.PubMed
67.
Helbig G. Imatinib for the treatment of hypereosinophilic syndromes. Expert Rev Clin Immunol. 2018;14:163–70.PubMed
68.
Curtis C, Ogbogu P. Hypereosinophilic syndrome. Clin Rev Allergy Immunol. 2016;50:240–51.PubMed
69.
Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Mepolizumab HES Study Group, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358:1215–28.PubMed
70.
Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013;131:461–7 (e1–5).PubMed
71.
Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg. 1996;15:250–7.PubMed
72.
Chaiken BH, Goldberg BI, Segal JP. Dilantin sensitivity; report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med. 1950;242:897–8.PubMed
73.
Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019. Allergol Int. 2019;68:301–8.PubMed
74.
Martínez-Cabriales SA, Rodríguez-Bolaños F, Shear NH. Drug reaction with eosinophilia and systemic symptoms (DReSS): how far have we come? Am J Clin Dermatol. 2019;20:217–36.PubMed
75.
Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, RegiSCAR Study Group, et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169:1071–80.PubMed
76.
Watanabe H. Recent advances in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. J Immunol Res. 2018;2018:5163129.PubMedPubMedCentral
77.
Marzano AV, Borghi A, Cugno M. Adverse drug reactions and organ damage: the skin. Eur J Intern Med. 2016;28:17–24.PubMed
78.
Ortonne N, Valeyrie-Allanore L, Bastuji-Garin S, Wechsler J, de Feraudy S, Duong TA, et al. Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study. Br J Dermatol. 2015;173:50–8.PubMed
79.
Funck-Brentano E, Duong TA, Bouvresse S, Bagot M, Wolkenstein P, Roujeau JC, et al. Therapeutic management of DRESS: a retrospective study of 38 cases. J Am Acad Dermatol. 2015;72:246–52.PubMed
80.
Weed RI. Exaggerated delayed hypersensitivity to mosquito bites in chronic lymphocytic leukemia. Blood. 1965;26:257–68.PubMed
81.
Byrd JA, Scherschun L, Chaffins ML, Fivenson DP. Eosinophilic dermatosis of myeloproliferative disease: characterization of a unique eruption in patients with hematologic disorders. Arch Dermatol. 2001;137:1378–80.PubMed
82.
Grandi V, Maglie R, Antiga E, Vannucchi M, Delfino C, Lastrucci I, et al. Eosinophilic dermatosis of hematologic malignancy: a retrospective cohort of 37 patients from an Italian center. J Am Acad Dermatol. 2019;81:246–9.PubMed
83.
Maglie R, Antiga E, Vannucchi M, Del Bianco E, Bianchi B, Massi D, Caproni M. Bullous eruption in a patient with B-cell chronic lymphocytic leukemia: a diagnostic challenge. Int J Dermatol. 2017;56:1445–7.PubMed
84.
Meiss F, Technau-Hafsi K, Kern JS, May AM. Eosinophilic dermatosis of hematologic malignancy: correlation of molecular characteristics of skin lesions and extracutaneous manifestations of hematologic malignancy. J Cutan Pathol. 2019;46:175–81.PubMed
85.
Farber MJ, La Forgia S, Sahu J, Lee JB. Eosinophilic dermatosis of hematologic malignancy. J Cutan Pathol. 2012;39:690–5.PubMed
86.
Jin A, Pousti BT, Savage KT, Mollanazar NK, Lee JB, Hsu S. Eosinophilic dermatosis of hematologic malignancy responding to dupilumab in a patient with chronic lymphocytic leukemia. JAAD Case Rep. 2019;5:815–7.PubMedPubMedCentral
87.
Asero R, Cugno M, Tedeschi A. Eosinophils in chronic urticaria: supporting or leading actors? World Allergy Organ J. 2009;2:213–7.PubMedPubMedCentral
88.
Yanase Y, Takahagi S, Hide M. Chronic spontaneous urticaria and the extrinsic coagulation system. Allergol Int. 2018;67:191–4.PubMed
89.
Tedeschi A, Asero R, Lorini M, Marzano AV, Cugno M. Serum eotaxin levels in patients with chronic spontaneous urticaria. Eur Ann Allergy Clin Immunol. 2012;44:188–92.PubMed
90.
Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R. Expression of tissue factor by eosinophils in patients with chronic urticaria. Int Arch Allergy Immunol. 2009;148:170–4.PubMed
91.
Tedeschi A, Asero R, Marzano AV, Lorini M, Fanoni D, Berti E, Cugno M. Plasma levels and skin-eosinophil-expression of vascular endothelial growth factor in patients with chronic urticaria. Allergy. 2009;64:1616–22.PubMed
92.
Kay AB, Ying S, Ardelean E, Mlynek A, Kita H, Clark P, et al. Elevations in vascular markers and eosinophils in chronic spontaneous urticarial weals with low-level persistence in uninvolved skin. Br J Dermatol. 2014;171:505–11.PubMedPubMedCentral
93.
94.
Eberle JU, Radtke D, Nimmerjahn F, Voehringer D. Eosinophils mediate basophil-dependent allergic skin inflammation in mice. J Investig Dermatol. 2019;139:1957–65 (e2).PubMed
95.
Shulman LE. Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians. 1975;88:70–86.PubMed
96.
Pinal-Fernandez I, Selva-O' Callaghan A, Grau JM. Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev. 2014;13:379–82.PubMed
97.
Gomes I, Mathur SK, Espenshade BM, Mori Y, Varga J, Ackerman SJ. Eosinophil-fibroblast interactions induce fibroblast IL-6 secretion and extracellular matrix gene expression: implications in fibrogenesis. J Allergy Clin Immunol. 2005;116:796–804.PubMed
98.
Mertens JS, Seyger MMB, Thurlings RM, Radstake TRDJ, de Jong EMGJ. Morphea and eosinophilic fasciitis: an update. Am J Clin Dermatol. 2017;18:491–512.PubMedPubMedCentral
99.
Lakhanpal S, Ginsburg WW, Michet CJ, Doyle JA, Moore SB. Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum. 1988;17:221–31.PubMed
100.
Fett N, Arthur M. Eosinophilic fasciitis: current concepts. Clin Dermatol. 2018;36:487–97.PubMed
101.
Toquet C, Hamidou MA, Renaudin K, Jarry A, Foulc P, Barbarot S, et al. In situ immunophenotype of the inflammatory infiltrate in eosinophilic fasciitis. J Rheumatol. 2003;30:1811–5.PubMed
102.
Mazori DR, Femia AN, Vleugels RA. Eosinophilic fasciitis: an updated review on diagnosis and treatment. Curr Rheumatol Rep. 2017;19:74.PubMed
103.
De Clerck LS, Degryse HR, Wouters E, Van Offel JF, De Schepper AM, Martin JJ, et al. Magnetic resonance imaging in the evaluation of patients with eosinophilic fasciitis. J Rheumatol. 1989;16:1270–3.PubMed
104.
Wright NA, Mazori DR, Patel M, Merola JF, Femia AN, Vleugels RA. Epidemiology and treatment of eosinophilic fasciitis: an analysis of 63 patients from 3 tertiary care centers. JAMA Dermatol. 2016;152:97–9.PubMed
105.
Mertens JS, Zweers MC, Kievit W, Knaapen HK, Gerritsen M, Radstake TR, et al. High-dose intravenous pulse methotrexate in patients with eosinophilic fasciitis. JAMA Dermatol. 2016;152:1262–5.PubMed
106.
Ise S, Ofuji S. Subcorneal pustular dermatosis: a follicular variant? Arch Dermatol. 1965;92(2):169–71.PubMed
107.
Nakahigashi K, Doi H, Otsuka A, Hirabayashi T, Murakami M, Urade Y, et al. PGD2 induces eotaxin-3 via PPARγ from sebocytes: a possible pathogenesis of eosinophilic pustular folliculitis. J Allergy Clin Immunol. 2012;129:536–43.PubMed
108.
Katoh M, Nomura T, Miyachi Y, Kabashima K. Eosinophilic pustular folliculitis: a review of the Japanese published works. J Dermatol. 2013;40:15–20.PubMed
109.
Fujiyama T, Tokura Y. Clinical and histopathological differential diagnosis of eosinophilic pustular folliculitis. J Dermatol. 2013;40:419–23.PubMed
110.
Hernández-Martín Á, Nuño-González A, Colmenero I, Torrelo A. Eosinophilic pustular folliculitis of infancy: a series of 15 cases and review of the literature. J Am Acad Dermatol. 2013;68:150–5.PubMed
111.
Rosenthal D, LeBoit PE, Klumpp L, Berger TG. Human immunodeficiency virus-associated eosinophilic folliculitis: a unique dermatosis associated with advanced human immunodeficiency virus infection. Arch Dermatol. 1991;127:206–9.PubMed
112.
Takamura S, Teraki Y. Eosinophilic pustular folliculitis associated with hematological disorders: a report of two cases and review of Japanese literature. J Dermatol. 2016;43:432–5.PubMed
113.
Fukamachi S, Kabashima K, Sugita K, Kobayashi M, Tokura Y. Therapeutic effectiveness of various treatments for eosinophilic pustular folliculitis. Acta Derm Venereol. 2009;89:155–9.PubMed
114.
115.
Cesinaro AM, Lonardi S, Facchetti F. Granuloma faciale: a cutaneous lesion sharing features with IgG4-associated sclerosing diseases. Am J Surg Pathol. 2013;37:66–73.PubMed
116.
Ortonne N, Wechsler J, Bagot M, Grosshans E, Cribier B. Granuloma faciale: a clinicopathologic study of 66 patients. J Am Acad Dermatol. 2005;53:1002–9.PubMed
117.
Lindhaus C, Elsner P. Granuloma faciale treatment: a systematic review. Acta Dermatovenereol. 2018;98:14–8.
118.
Wells GC, Whimster IW. Subcutaneous angiolymphoid hyperplasia with eosinophilia. Br J Dermatol. 1969;81:1–14.PubMed
119.
Tokat F, Lehman JS, Sezer E, Cetin ED, Ince U, Durmaz EO. Immunoreactivity of Wilms tumor 1 (WT1) as an additional evidence supporting hemangiomatous rather than inflammatory origin in the etiopathogenesis of angiolymphoid hyperplasia with eosinophilia. Dermatol Pract Concept. 2018;8:28–322.PubMedPubMedCentral
120.
Adler BL, Krausz AE, Minuti A, Silverberg JI, Lev-Tov H. Epidemiology and treatment of angiolymphoid hyperplasia with eosinophilia (ALHE): a systematic review. J Am Acad Dermatol. 2016;74:506–12 (e11).PubMed
121.
Olsen TG, Helwig EB. Angiolymphoid hyperplasia with eosinophilia: a clinicopathologic study of 116 patients. J Am Acad Dermatol. 1985;12:781–96.PubMed
122.
Marzano AV, Raimondo MG, Berti E, Meroni PL, Ingegnoli F. Cutaneous manifestations of ANCA-associated small vessels vasculitis. Clin Rev Allergy Immunol. 2017;53:428–38.PubMed
123.
Furuta S, Iwamoto T, Nakajima H. Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019;68:430–6.PubMed
124.
Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol. 2008;9:71–92.PubMed
125.
Marques CC, Fernandes EL, Miquelin GM, Colferai MMT. Cutaneous manifestations of Churg–Strauss syndrome: key to diagnosis. An Bras Dermatol. 2017;92:56–8.PubMedPubMedCentral
126.
Josselin-Mahr L, Werbrouck-Chiraux A, Garderet L, Cabane J. Efficacy of imatinib mesylate in a case of Churg–Strauss syndrome: evidence for the pathogenic role of a tyrosine kinase? Rheumatology (Oxford). 2014;53:378–9.
127.
Erre GL, Pardini S, Cuccuru L, Taras L, Passiu G. Is there a role for imatinib mesylate in the treatment of eosinophilic granulomatosis with polyangiitis? Jt Bone Spine. 2015;82:72–3.
128.
Simon D, Simon HU. Therapeutic strategies for eosinophilic dermatoses. Curr Opin Pharmacol. 2019;46:29–33.PubMed
129.
Wakugawa M, Nakamura K, Hino H, Toyama K, Hattori N, Okochi H, et al. Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia. Br J Dermatol. 2000;143:112–6.PubMed
130.
Alsorori E, Kiss N, Medvecz M, Naqeshbandi AF, Bergler-Czop B, Alsarari I, et al. A case of granuloma faciale successfully treated with systemic dapsone. Dermatol Ther. 2019;8:e13162 (Epub ahead of print).
131.
Montgomery JR, Chan LS. An unusual clinical presentation of pemphigus herpetiformis with marked response to dapsone. J Am Acad Dermatol. 2011;65:436–8.PubMed
132.
Bozeman PM, Learn DB, Thomas EL. Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Biochem Pharmacol. 1992;44:553–63.PubMed
133.
Günther C, Wozel G, Meurer M, Pfeiffer C. Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid. Clin Exp Immunol. 2011;166:145–53.PubMedPubMedCentral
134.
Buttgereit T, Bonnekoh H, Church MK, Bergmann KC, Siebenhaar F, Metz M. Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab. J Dtsch Dermatol Ges. 2019;17:1171–2.PubMed
135.
Kuruvilla M. Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab. Ann Allergy Asthma Immunol. 2018;120:670–1.PubMed
136.
Dávila González I, Moreno Benítez F, Quirce S. Benralizumab: a new approach for the treatment of severe eosinophilic asthma. J Investig Allergol Clin Immunol. 2019;29:84–93.PubMed
137.
Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005;60:693–6.PubMed
138.
139.
Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, EGPA Mepolizumab Study, et al. Team Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376:1921–32.PubMedPubMedCentral
140.
Faverio P, Bonaiti G, Bini F, Vaghi A, Pesci A. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy. Ther Clin Risk Manag. 2018;14:2385–96.PubMedPubMedCentral
141.
Kunsleben N, Rüdrich U, Gehring M, Novak N, Kapp A, Raap U. IL-31 induces chemotaxis, calcium mobilization, release of reactive oxygen species, and CCL26 in eosinophils, which are capable to release IL-31. J Investig Dermatol. 2015;135:1908–11.PubMed
142.
Gibbs BF, Patsinakidis N, Raap U. Role of the pruritic cytokine IL-31 in autoimmune skin diseases. Front Immunol. 2019;10:1383.PubMedPubMedCentral
143.
Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, XCIMA Study Group, et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017;376:826–35.PubMed
144.
Silverberg JI, Pinter A, Pulka G, Poulin Y, Bouaziz JD, Wollenberg A, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145:173–82.PubMed
145.
Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–9.PubMed
146.
Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taïeb A, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78:863–71 (e11).PubMed
147.
Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143:135–41.PubMed
148.
Hirano I, Dellon ES, Hamilton JD, Collins MH, Peterson K, Chehade M, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158:111–22 (e10).PubMed
149.
Kaye A, Gordon SC, Deverapalli SC, Her MJ, Rosmarin D. Dupilumab for the treatment of recalcitrant bullous pemphigoid. JAMA Dermatol. 2018;154:1225–6.PubMed
150.
Dworetzky SI, Hebrank GT, Archibald DG, Reynolds IJ, Farwell W, Bozik ME. The targeted eosinophil-lowering effects of dexpramipexole in clinical studies. Blood Cells Mol Dis. 2017;63:62–5.PubMed
151.
Panch SR, Bozik ME, Brown T, Makiya M, Prussin C, Archibald DG, et al. Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes. Blood. 2018;132:501–9.PubMedPubMedCentral
152.
O'Sullivan JA, Carroll DJ, Cao Y, Salicru AN, Bochner BS. Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells. J Allergy Clin Immunol. 2018;141:1774–85 (e7).PubMed
153.
Youngblood BA, Brock EC, Leung J, Falahati R, Bochner BS, Rasmussen HS, et al. Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis. JCI Insight. 2019;4(19):126219 (Epub ahead of print).PubMed
154.
Marcus N, Smuel K, Almog M, Prais D, Straussberg R, Landau D, et al. Successful intravenous immunoglobulin treatment in pediatric severe DRESS syndrome. J Allergy Clin Immunol Pract. 2018;6:1238–42.PubMed
155.
von Gunten S, Vogel M, Schaub A, Stadler BM, Miescher S, Crocker PR, et al. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol. 2007;119:1005–111.
156.
Walker S, Wang C, Walradt T, Hong BS, Tanner JR, Levinsohn JL, et al. Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. Blood. 2016;12:948–51.
157.
King B, Lee AI, Choi J. Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib. J Investig Dermatol. 2017;137:951–4.PubMed
158.
Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175(5):902–11.PubMed
159.
Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80:913–21 (e9).PubMed
160.
Guttman-Yassky E, Thaçi D, Pangan AL, Hong HC, Papp KA, Reich K, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2019 (Epub ahead of print)
161.
Kim SR, Charos A, Damsky W, Heald P, Girardi M, King BA. Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. JAAD Case Rep. 2018;4:443–5.PubMedPubMedCentral
Metadata
Title
Eosinophilic Dermatoses: Recognition and Management
Authors
Angelo Valerio Marzano
Giovanni Genovese
Publication date
01-08-2020
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 4/2020
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-020-00520-4

Other articles of this Issue 4/2020

American Journal of Clinical Dermatology 4/2020 Go to the issue

Leading Article

New and Emerging Biologics for Atopic Dermatitis

Original Research Article

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

Original Research Article

Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice

Review Article

Dermatologic Sequelae Associated with Radiation Therapy

Review Article

A Review Comparing International Guidelines for the Management of Bullous Pemphigoid, Pemphigoid Gestationis, Mucous Membrane Pemphigoid, and Epidermolysis Bullosa Acquisita

Evidence-Based Review Article

Fabric Selection in Atopic Dermatitis: An Evidence-Based Review